{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:12Z","timestamp":1787008392150,"version":"build-2736575974"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":2503,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1093\/annonc\/mds517","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T23:30:57Z","timestamp":1353627057000},"page":"561-576","source":"Crossref","is-referenced-by-count":186,"title":["ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Ghielmini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Caligaris-Cappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Agostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gomes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Iannitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Lopez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds517_bb0010","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mds517_bb0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1093\/annonc\/mds517_bb0020","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0030","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0035","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0040","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0045","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkins lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0050","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds517_bb0060","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"9806","key":"10.1093\/annonc\/mds517_bb0070","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03\u20132B): an open-label randomised phase 3 trial.","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds517_bb0075","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8000","article-title":"R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma","volume":"29","author":"Cunningham","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0080","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1989.7.8.1018","article-title":"LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma","volume":"7","author":"Coiffier","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0085","first-page":"69","article-title":"Intensification of CHOEP regimen for high-grade Non-Hodgkins-Lymphoma by G-CSF - Feasibility of a 14-day regimen","volume":"17","author":"Trumper","year":"1994","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mds517_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004024.pub2","article-title":"High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults","author":"Greb","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mds517_bb0095","first-page":"8001","volume":"29","author":"Stiff","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1093\/annonc\/mds517_bb0100","volume":"22","author":"Vitolo","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/annonc\/mdr197","volume":"22","author":"Schmitz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0110","first-page":"685","article-title":"No benefit of first-line rituximab (R)\u2014high-dose therapy (R-HDT) over R-CHOP14 for young adults with diffuse large B-cell lymphoma. preliminary results of the GOELAMS 075 prospective multicentre randomized trial","volume":"116","author":"Milpied","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds517_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0120","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds517_bb0130","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0135","article-title":"R-CHOP14 Compared to R-CHOP21in elderly patients with diffuse large B-cell lymphoma(DLBCL): results of the second interim analysis of the LNH03\u20136B GELA study","volume":"22","author":"Delarue","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mds517_bb0145","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin\u010fs lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0150","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0155","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0165","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/cncr.20587","article-title":"Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"101","author":"Crump","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds517_bb0170","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1002\/cncr.25216","article-title":"Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) \u00b1 rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma","volume":"116","author":"Rigacci","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds517_bb0175","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European group for blood and marrow transplantation registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0180","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mds517_bb0185","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mds517_bb0190","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0195","first-page":"522","article-title":"18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review","volume":"91","author":"Zijlstra","year":"2006","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mds517_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2967\/jnumed.107.039867","article-title":"18F-FDG PET for posttherapy assessment of hodgkin's disease and aggressive non-hodgkin's lymphoma: a systematic review","volume":"49","author":"Terasawa","year":"2008","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1093\/annonc\/mds517_bb0205","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"The interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0210","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2009-08-234351","article-title":"Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study","volume":"115","author":"Horning","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0215","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0220","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1200\/JCO.2008.16.1513","article-title":"Role of [18F] fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma","volume":"27","author":"Luigi Zinzani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1200\/jco.2004.22.90140.6521","article-title":"Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone","volume":"22","author":"Petersen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-009-1937-4","article-title":"Long term outcome and prognostic factors in early stage nodal low grade non-Hodgkins lymphomas treated with radiation therapy","volume":"185","author":"Eich","year":"2009","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mds517_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non Hodgkins lymphoma: a randomised Phase III trial","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mds517_bb0240","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.ejca.2005.04.033","article-title":"Effective palliation by low dose local radiotherapy for recurrent and\/or chemotherapy refractory non-follicular lymphoma patients","volume":"41","author":"Haas","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mds517_bb0245","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0250","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0255","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/oxfordjournals.annonc.a010720","article-title":"Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center","volume":"7","author":"Soubeyran","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0260","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.25149","article-title":"Improved survival in patients with low grade follicular lymphoma treated with radiation","volume":"116","author":"Pugh","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds517_bb0265","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds517_bb0270","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Grouped'Etude des LymphomesFolliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0275","first-page":"11","article-title":"The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Haematol"},{"key":"10.1093\/annonc\/mds517_bb0280","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJM198412063112303","article-title":"The natural history of initially untreated low-grade non-Hodgkin's lymphomas","volume":"311","author":"Horning","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0285","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0290","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0295","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0300","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in pateints with previously untreated advanced follicualr lymphoma","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0305","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0310","first-page":"168","volume":"110","author":"Rummel","year":"2009","journal-title":"Blood"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mds517_bb0315","first-page":"128","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced stage Follicular Lymphoma. Preliminary results of FOLL05 IIL trial. IX ICML Lugano, Switzerland, 15\u201318 June 2011","volume":"22","author":"Federico","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0320","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"29","key":"10.1093\/annonc\/mds517_bb0325","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds517_bb0330","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mds517_bb0335","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0340","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0345","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0350","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds517_bb0355","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0360","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0365","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds517_bb0370","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0375","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mds517_bb0380","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","article-title":"Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study","volume":"96","author":"Le Gouill","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"10.1093\/annonc\/mds517_bb0385","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2189.2189","article-title":"Impact of autologous stem cell transplantation and\/or rituximab on outcome of patients with relapsed follicular lymphoma\u2014retrospective analysis of 2 randomized trials of the German Low Grade Lymphoma Study Group (GLSG)","volume":"112","author":"Weigert","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2008.07067.x","article-title":"Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma","volume":"141","author":"Ingram","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mds517_bb0395","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mds517_bb0400","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","article-title":"Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"22","author":"Eichhorst","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds517_bb0405","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","author":"Dearden","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1093\/annonc\/mds517_bb0410","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2010.036152","article-title":"Chronic lymphocytic leukemia and autoimmunity: a systematic review","volume":"96","author":"Hodgson","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1093\/annonc\/mds517_bb0415","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1093\/annonc\/mds517_bb0420","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428190903026492","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia\/small lymphocytic lymphoma: changes in clinical presentation and prognosis","volume":"50","author":"Zent","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1093\/annonc\/mds517_bb0425","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2010-05-286500","article-title":"Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance","volume":"116","author":"Moreno","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds517_bb0430","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/CCO.0b013e328348c683","article-title":"A matter of debate in chronic lymphocytic leukemia (CLL): is the occurrence of autoimmune disorders an indicator of CLL therapy?","volume":"23","author":"Strati","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mds517_bb0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mds517_bb0440","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0445","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0450","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mds517_bb0455","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"issue":"29","key":"10.1093\/annonc\/mds517_bb0460","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0465","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mds517_bb0470","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"9747","key":"10.1093\/annonc\/mds517_bb0475","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds517_bb0480","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1093\/annonc\/mds517_bb0485","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds517_bb0490","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11864-011-0161-5","article-title":"Basic assessment of the older cancer patient","volume":"12","author":"Extermann","year":"2011","journal-title":"Curr Treat Options Oncol"},{"issue":"26","key":"10.1093\/annonc\/mds517_bb0495","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicentre phase II trial of the German CLL Study Group","volume":"10","author":"Fischer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mds517_bb0500","first-page":"1268","article-title":"Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy","volume":"85","author":"Marotta","year":"2000","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mds517_bb0505","article-title":"Fludarabine (F) administered on a three (F3a) alternate day-basis in selected CLL patients [abstract no. 53]","volume":"42","author":"Bezares","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1093\/annonc\/mds517_bb0510","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/hon.868","article-title":"Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukaemia","volume":"26","author":"Forconi","year":"2008","journal-title":"Hematol Oncol"},{"issue":"13","key":"10.1093\/annonc\/mds517_bb0515","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2012-01-408047","article-title":"Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia","volume":"119","author":"Foon","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0520","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2009-02-206185","article-title":"German CLL Study Group (GCLLSG): first-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"issue":"9583","key":"10.1093\/annonc\/mds517_bb0525","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"10.1093\/annonc\/mds517_bb0530","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mds517_bb0535","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"10","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0540","first-page":"3428","article-title":"An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL)","volume":"114","author":"Hillmen","year":"2009","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds517_bb0545","first-page":"2462","article-title":"A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis","volume":"116","author":"Foa","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1093\/annonc\/mds517_bb0550","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1093\/annonc\/mds517_bb0555","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Hx-CD20\u2013406 Study Investigators. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0560","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds517_bb0565","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0570","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H trial of the GCLLSG","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0575","first-page":"58","article-title":"Interim analysis of EFC6663, a multicenter phase 2 study of alvocidib (flavopiridol), demonstrates clinical responses among patients with fludarabine refractory CLL","volume":"116","author":"Lanasa","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"11","key":"10.1093\/annonc\/mds517_bb0580","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds517_bb0585","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1093\/annonc\/mds517_bb0590","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","article-title":"Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial","volume":"92","author":"Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds517_bb0595","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mds517_bb0600","first-page":"2357","article-title":"Allogeneic stem cell transplantation can overcome the adverse prognostic impact of TP53 mutation in chronic lymphocytic leukemia (CLL): results from the GCLLSG CLL3x trial","volume":"116","author":"Zenz","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1093\/annonc\/mds517_bb0605","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/asheducation-2010.1.481","article-title":"Understanding and managing ultra-high-risk chronic lymphocytic leukemia","author":"Stilgenbauer","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"10.1093\/annonc\/mds517_bb0610","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood.V114.22.2381.2381","article-title":"Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia [Abstract]","volume":"114","author":"Keating","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0615","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds517_bb0620","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J ClinOncol"},{"key":"10.1093\/annonc\/mds517_bb0625","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mds517_bb0630","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-05-0941","article-title":"Allogeneic Transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities","volume":"11","author":"Caballero","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mds517_bb0635","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3324\/haematol.2008.000273","article-title":"Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation","volume":"94","author":"Farina","year":"2009","journal-title":"Haematologica"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419371431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419371431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/3\/561\/541034\/mds517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T03:35:42Z","timestamp":1624678542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419371431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0923753419371431"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds517","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}